XML 55 R19.htm IDEA: XBRL DOCUMENT
v3.20.4

BUSINESS CONCENTRATIONS | 12 Months Ended
--- | ---
Dec. 31, 2020
Risks and Uncertainties [Abstract] |
BUSINESS CONCENTRATIONS | NOTE 13 - BUSINESS CONCENTRATIONS We purchase our prescription products from several suppliers with approximately 36%, 30% and 25% of our purchases supplied by three vendors each, respectively, during the year ended December 31, 2020, 24%, 27% and 35% of our purchases supplied by three vendors each, respectively, during the year ended December 31, 2019, and 43%, 33% and 24% of our purchases supplied by three vendors each, respectively, during the year ended December 31, 2018. We sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the year ended December 31, 2020, three customers each accounted for more than 10% of our total product revenue. During each of the years ended December 31, 2019 and 2018, four customers each accounted for more than 10% of our total product revenue. Product revenue from the three customers combined accounted for approximately 63% of our product revenue for the year ended December 31, 2020. Product revenue from the four customers combined accounted for approximately 73% and 76% of our product revenue for the years ended December 31, 2019 and 2018, respectively. During the year ended December 31, 2020, Cardinal Health accounted for approximately $17,489,000 of our product revenue, Pillpack, Inc. accounted for approximately $13,228,000 of our product revenue, and McKesson Corporation accounted for approximately $9,862,000 of our product revenue. During the year ended December 31, 2019, Pillpack, Inc. accounted for approximately $12,676,000 of our product revenue, Cardinal Health accounted for approximately $4,551,000 of our product revenue, AmerisourceBergen accounted for approximately $3,927,000 of our product revenue and McKesson Corporation accounted for approximately $3,911,000 of our product revenue. During the year ended December 31, 2018, Pillpack, Inc. accounted for approximately $5,075,000 of our product revenue, AmerisourceBergen accounted for approximately $3,246,000 of our product revenue and Cardinal Health accounted for approximately $2,308,000 of our product revenue, and McKesson Corporation accounted for approximately $1,610,000 of our product revenue.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration